Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.78 |
| ▸ | KDR | P35968 | 4/20 | 0.73 |
| ▸ | FLT1 | P17948 | 2/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.73 |
| ▸ | ILK | Q13418 | 2/20 | 0.73 |
| ▸ | KDM1A | O60341 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 2/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | PLK4 | O00444 | 1/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.73 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | BUB1 | O43683 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.73 |
| ▸ | STK17B | O94768 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8870869 | 0.99 | EGFR (0.76) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL2099775 | 0.97 | EGFR (0.83) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL8872430 | 0.88 | EGFR (0.72) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL20805304 | 0.88 | EGFR (0.77) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL21388275 | 0.88 | EGFR (0.62) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL14551678 | 0.87 | FBP1 (0.77) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL18447218 | 0.87 | KDM1A (0.77) | EGFRKDRFLT1ERBB2ILK | |
| SCHEMBL2100996 | 0.87 | EGFR (0.77) | EGFRERBB2FBP1ERBB4 | |
| SCHEMBL2101009 | 0.87 | EGFR (0.81) | EGFRKDRFLT1ERBB2GAK | |
| SCHEMBL8870965 | 0.87 | EGFR (0.81) | EGFRKDRFLT1ERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | claimed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230218572-A1 | COMPOSITIONS AND METHODS FOR IMPROVED MESENCHYMAL STEM CELL THERAPY | University of Hong Kong Versitech Limited (CN) | 2023-07-13 | — | — | US | disclosed |
| US-11672812-B2 | Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer | CITY OF HOPE (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3340990-B1 | PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018112111-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TARGETED PHOTOSENSITIZERS | HEALTH RESEARCH, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-9220696-B2 | Pharmaceutical combinations for treatment of specific cancers | ARDEA BIOSCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
| EP-1853300-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | Genentech, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672812-B2 | Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer | FLT3, ABL1, TNNI3K | EGFR 184/4885KDR 375/4885FLT1 274/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 34/4885FLT1 46/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885KDR 50/4885FLT1 253/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885KDR 34/4885FLT1 46/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885KDR 33/4885FLT1 18/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | EGFR 2906/4885KDR 1483/4885FLT1 1412/4885 |
| US-20230218572-A1 | COMPOSITIONS AND METHODS FOR IMPROVED MESENCHYMAL STEM CELL THERAPY | LDLR, HMGCR, CD59 | EGFR 19/4885KDR 433/4885FLT1 1636/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | EGFR 2906/4885KDR 1483/4885FLT1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.